ITRM - Iterum Therapeutics plc
NASDAQ
->
Healthcare
->
Biotechnology
Dublin,
Ireland
Type: Equity
ITRM price evolution
ITRM
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5.01 | $7.42 | $6.11 | |
| Short term investments | $6.74 | $10.82 | $17.86 | |
| Net receivables | $0.21 | $0.18 | $0.04 | |
| Inventory | ||||
| Total current assets | $15.85 | $13.7 | $19.05 | $25.6 |
| Long term investments | ||||
| Property, plant & equipment | $0.03 | $0.04 | $0.04 | $0.05 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.48 | $0.57 | $0.66 | |
| Total investments | $6.74 | $10.82 | $17.86 | |
| Total assets | $15.92 | $14.17 | $19.63 | $26.26 |
| Current liabilities | ||||
| Accounts payable | $0.83 | $0.82 | $2.97 | $5 |
| Deferred revenue | ||||
| Short long term debt | $12.95 | $12.2 | ||
| Total current liabilities | $18.7 | $16.77 | $17.79 | $13.52 |
| Long term debt | $8.73 | $8.3 | $7.89 | $18.96 |
| Total noncurrent liabilities | $8.31 | $7.98 | $19.14 | |
| Total debt | $21.25 | $20.09 | $18.96 | |
| Total liabilities | $27.43 | $25.09 | $25.77 | $32.66 |
| Shareholders' equity | ||||
| Retained earnings | -$479.49 | -$473.4 | -$468.4 | -$461.3 |
| Other shareholder equity | $0 | -$0 | $0 | |
| Total shareholder equity | -$10.91 | -$6.15 | -$6.4 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $6.11 | $21.13 | $27.45 | $14.57 |
| Short term investments | $17.86 | $39.71 | $53.9 | |
| Net receivables | $0.04 | $0.4 | $0.36 | $0.06 |
| Inventory | ||||
| Total current assets | $25.6 | $62.44 | $83.27 | $21.47 |
| Long term investments | $0.06 | $0.25 | ||
| Property, plant & equipment | $0.05 | $1.84 | $0.09 | $0.42 |
| Goodwill & intangible assets | $1.72 | $3.44 | ||
| Total noncurrent assets | $0.66 | $4.39 | $8.24 | $11.32 |
| Total investments | $17.86 | $39.71 | $53.96 | $0.25 |
| Total assets | $26.26 | $66.83 | $91.51 | $32.79 |
| Current liabilities | ||||
| Accounts payable | $5 | $2.77 | $0.88 | $0.82 |
| Deferred revenue | ||||
| Short long term debt | $1.63 | $6.49 | ||
| Total current liabilities | $13.52 | $9.06 | $12.94 | $41.7 |
| Long term debt | $18.96 | $28.47 | $24.9 | $35.85 |
| Total noncurrent liabilities | $19.14 | $29.77 | $28.33 | $41.65 |
| Total debt | $18.96 | $28.47 | $26.52 | $42.34 |
| Total liabilities | $32.66 | $38.83 | $41.27 | $83.35 |
| Shareholders' equity | ||||
| Retained earnings | -$461.3 | -$422.93 | -$378.49 | -$286.93 |
| Other shareholder equity | $0 | -$0.35 | ||
| Total shareholder equity | -$6.4 | $28 | $50.23 | -$50.56 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $2.08 | $3.98 | $9.74 | |
| Selling, general & administrative | $1.9 | $2.19 | $1.69 | |
| Total operating expenses | $3.98 | $6.16 | $11.43 | |
| Operating income | -$3.98 | -$6.16 | -$11.43 | |
| Income from continuing operations | ||||
| EBIT | -$4.39 | -$6.57 | -$11.81 | |
| Income tax expense | $0.03 | $0.05 | $0.14 | |
| Interest expense | $0.57 | $0.49 | $0.41 | |
| Net income | ||||
| Net income | -$5 | -$7.1 | -$12.36 | |
| Income (for common shares) | -$5 | -$7.1 | -$12.36 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $39.99 | $17.62 | $10.71 | $21.07 |
| Selling, general & administrative | $7.48 | $12.77 | $13.82 | $11.05 |
| Total operating expenses | $47.47 | $30.38 | $24.54 | $32.13 |
| Operating income | -$47.47 | -$30.38 | -$24.54 | -$32.13 |
| Income from continuing operations | ||||
| EBIT | -$36.33 | -$41.77 | -$85.31 | -$36.17 |
| Income tax expense | $0.61 | $0.3 | $0.7 | $0.74 |
| Interest expense | $1.43 | $2.36 | $5.55 | $15.1 |
| Net income | ||||
| Net income | -$38.37 | -$44.43 | -$91.56 | -$52.01 |
| Income (for common shares) | -$38.37 | -$44.43 | -$91.56 | -$52.01 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$5 | -$7.1 | -$12.36 | |
| Operating activities | ||||
| Depreciation | $0.01 | $0.01 | $0.44 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.07 | $0.14 | $0.14 | |
| Total cash flows from operations | -$6.76 | -$13.08 | -$12.84 | |
| Investing activities | ||||
| Capital expenditures | -$0 | |||
| Investments | $4.2 | $7.21 | $13.52 | |
| Total cash flows from investing | $17.11 | $4.2 | $7.21 | $13.52 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.17 | $7.22 | $0.59 | |
| Net borrowings | ||||
| Total cash flows from financing | $12.81 | $0.17 | $7.22 | $0.59 |
| Effect of exchange rate | -$0.07 | -$0.02 | -$0.03 | -$0.01 |
| Change in cash and equivalents | $7.34 | -$2.41 | $1.32 | $1.25 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$38.37 | -$44.43 | -$91.56 | -$52.01 |
| Operating activities | ||||
| Depreciation | $1.75 | $1.8 | $2.1 | $0.16 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.78 | $4.76 | $4.32 | $2.76 |
| Total cash flows from operations | -$39.33 | -$18.47 | -$15.84 | -$54.53 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.06 | -$0.06 | -$0.01 |
| Investments | $23.35 | $14.02 | -$54.53 | |
| Total cash flows from investing | $23.34 | $13.96 | -$54.59 | -$0.01 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.03 | $0.43 | $89.64 | $69.96 |
| Net borrowings | -$2.25 | -$6.52 | -$5.49 | |
| Total cash flows from financing | $1.03 | -$1.82 | $83.13 | $64.47 |
| Effect of exchange rate | -$0.06 | -$0.05 | $0 | -$0.01 |
| Change in cash and equivalents | -$15.02 | -$6.38 | $12.69 | $9.93 |
News
Fundamentals
| Market cap | $25.20M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 22.71M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | -5.10 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.85 |
| Quick ratio | N/A |